×
S&P 500   3,809.94 (-0.40%)
DOW   30,784.73 (-1.01%)
QQQ   285.84 (+1.31%)
AAPL   141.29 (+1.70%)
MSFT   261.83 (+0.87%)
META   167.01 (+4.36%)
GOOGL   2,258.70 (+3.86%)
AMZN   113.77 (+3.84%)
TSLA   695.01 (+1.94%)
NVDA   148.92 (+2.54%)
NIO   21.95 (+2.76%)
BABA   118.09 (+1.80%)
AMD   74.90 (+1.67%)
MU   56.53 (+5.37%)
CGC   2.68 (-4.63%)
T   21.04 (-1.27%)
GE   61.36 (-3.43%)
F   11.12 (-1.77%)
DIS   96.74 (+0.62%)
AMC   12.68 (-6.28%)
PFE   51.30 (-1.93%)
PYPL   74.28 (+4.03%)
NFLX   184.50 (+2.53%)
S&P 500   3,809.94 (-0.40%)
DOW   30,784.73 (-1.01%)
QQQ   285.84 (+1.31%)
AAPL   141.29 (+1.70%)
MSFT   261.83 (+0.87%)
META   167.01 (+4.36%)
GOOGL   2,258.70 (+3.86%)
AMZN   113.77 (+3.84%)
TSLA   695.01 (+1.94%)
NVDA   148.92 (+2.54%)
NIO   21.95 (+2.76%)
BABA   118.09 (+1.80%)
AMD   74.90 (+1.67%)
MU   56.53 (+5.37%)
CGC   2.68 (-4.63%)
T   21.04 (-1.27%)
GE   61.36 (-3.43%)
F   11.12 (-1.77%)
DIS   96.74 (+0.62%)
AMC   12.68 (-6.28%)
PFE   51.30 (-1.93%)
PYPL   74.28 (+4.03%)
NFLX   184.50 (+2.53%)
S&P 500   3,809.94 (-0.40%)
DOW   30,784.73 (-1.01%)
QQQ   285.84 (+1.31%)
AAPL   141.29 (+1.70%)
MSFT   261.83 (+0.87%)
META   167.01 (+4.36%)
GOOGL   2,258.70 (+3.86%)
AMZN   113.77 (+3.84%)
TSLA   695.01 (+1.94%)
NVDA   148.92 (+2.54%)
NIO   21.95 (+2.76%)
BABA   118.09 (+1.80%)
AMD   74.90 (+1.67%)
MU   56.53 (+5.37%)
CGC   2.68 (-4.63%)
T   21.04 (-1.27%)
GE   61.36 (-3.43%)
F   11.12 (-1.77%)
DIS   96.74 (+0.62%)
AMC   12.68 (-6.28%)
PFE   51.30 (-1.93%)
PYPL   74.28 (+4.03%)
NFLX   184.50 (+2.53%)
S&P 500   3,809.94 (-0.40%)
DOW   30,784.73 (-1.01%)
QQQ   285.84 (+1.31%)
AAPL   141.29 (+1.70%)
MSFT   261.83 (+0.87%)
META   167.01 (+4.36%)
GOOGL   2,258.70 (+3.86%)
AMZN   113.77 (+3.84%)
TSLA   695.01 (+1.94%)
NVDA   148.92 (+2.54%)
NIO   21.95 (+2.76%)
BABA   118.09 (+1.80%)
AMD   74.90 (+1.67%)
MU   56.53 (+5.37%)
CGC   2.68 (-4.63%)
T   21.04 (-1.27%)
GE   61.36 (-3.43%)
F   11.12 (-1.77%)
DIS   96.74 (+0.62%)
AMC   12.68 (-6.28%)
PFE   51.30 (-1.93%)
PYPL   74.28 (+4.03%)
NFLX   184.50 (+2.53%)
NASDAQ:CKPT

Checkpoint Therapeutics Stock Forecast, Price & News

$1.05
+0.01 (+0.96%)
(As of 07/5/2022 02:33 PM ET)
Add
Compare
Today's Range
$1.04
$1.06
50-Day Range
$0.97
$1.45
52-Week Range
$0.96
$4.64
Volume
4,319 shs
Average Volume
460,271 shs
Market Capitalization
$95.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.00

Checkpoint Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
2,196.7% Upside
$24.00 Price Target
Short Interest
Healthy
3.57% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.63
Upright™ Environmental Score
News Sentiment
-0.35mentions of Checkpoint Therapeutics in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$320,160 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.70) to ($0.81) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.89 out of 5 stars

Medical Sector

620th out of 1,428 stocks

Pharmaceutical Preparations Industry

302nd out of 680 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive CKPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Checkpoint Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Checkpoint Therapeutics logo

About Checkpoint Therapeutics (NASDAQ:CKPT) Stock

Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

CKPT Stock News Headlines

Checkpoint Therapeutics GAAP EPS of -$0.20
Novato PD To Hold DUI Checkpoint
DUI Checkpoint Scheduled In Lake Elsinore
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CKPT
Fax
N/A
Employees
14
Year Founded
N/A

Company Calendar

Last Earnings
5/12/2022
Today
7/05/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$24.00
High Stock Price Forecast
$26.00
Low Stock Price Forecast
$20.00
Forecasted Upside/Downside
+1,804.8%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
1 Analysts

Profitability

Net Income
$-56,670,000.00
Net Margins
-26,592.46%
Pretax Margin
-26,592.46%

Debt

Sales & Book Value

Annual Sales
$270,000.00
Book Value
$0.34 per share

Miscellaneous

Free Float
85,473,000
Market Cap
$95.58 million
Optionable
Not Optionable
Beta
1.77














Checkpoint Therapeutics Frequently Asked Questions

Should I buy or sell Checkpoint Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Checkpoint Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Checkpoint Therapeutics stock.
View analyst ratings for Checkpoint Therapeutics
or view top-rated stocks.

What is Checkpoint Therapeutics' stock price forecast for 2022?

1 Wall Street research analysts have issued 12-month price objectives for Checkpoint Therapeutics' stock. Their CKPT stock forecasts range from $20.00 to $26.00. On average, they predict Checkpoint Therapeutics' share price to reach $24.00 in the next twelve months. This suggests a possible upside of 2,185.7% from the stock's current price.
View analysts' price targets for Checkpoint Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Checkpoint Therapeutics' stock price performed in 2022?

Checkpoint Therapeutics' stock was trading at $3.11 at the beginning of 2022. Since then, CKPT stock has decreased by 66.2% and is now trading at $1.05.
View the best growth stocks for 2022 here
.

When is Checkpoint Therapeutics' next earnings date?

Checkpoint Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Checkpoint Therapeutics
.

How were Checkpoint Therapeutics' earnings last quarter?

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) issued its earnings results on Thursday, May, 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by $0.09. The business earned $0.05 million during the quarter, compared to analysts' expectations of $0.07 million. Checkpoint Therapeutics had a negative trailing twelve-month return on equity of 173.15% and a negative net margin of 26,592.46%.
View Checkpoint Therapeutics' earnings history
.

Who are Checkpoint Therapeutics' key executives?

Checkpoint Therapeutics' management team includes the following people:

What other stocks do shareholders of Checkpoint Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Checkpoint Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), PTC Therapeutics (PTCT), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Aldeyra Therapeutics (ALDX), Kadmon (KDMN) and Rigel Pharmaceuticals (RIGL).

What is Checkpoint Therapeutics' stock symbol?

Checkpoint Therapeutics trades on the NASDAQ under the ticker symbol "CKPT."

How do I buy shares of Checkpoint Therapeutics?

Shares of CKPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Checkpoint Therapeutics' stock price today?

One share of CKPT stock can currently be purchased for approximately $1.05.

How much money does Checkpoint Therapeutics make?

Checkpoint Therapeutics (NASDAQ:CKPT) has a market capitalization of $95.58 million and generates $270,000.00 in revenue each year. The company earns $-56,670,000.00 in net income (profit) each year or ($0.85) on an earnings per share basis.

How many employees does Checkpoint Therapeutics have?

Checkpoint Therapeutics employs 14 workers across the globe.

How can I contact Checkpoint Therapeutics?

Checkpoint Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The official website for Checkpoint Therapeutics is www.checkpointtx.com. The company can be reached via phone at (781) 652-4500 or via email at investor@chimerareit.com.

This page (NASDAQ:CKPT) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.